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OBJECTIVE—To compare the pharmacokinetics and pharmacodynamics of NPH, glargine,
and detemir insulins in type 2 diabetic subjects.
RESEARCH DESIGN AND METHODS—This study used a single-blind, three-way,
cross-over design. A total of 18 type 2 diabetic subjects underwent a euglycemic clamp for
32 h after a subcutaneous injection of 0.4 units/kg at 2200 h of either NPH, glargine, or detemir
after 1 week of bedtime treatment with each insulin.
RESULTS—The glucose infusion rate area under the curve0–32 h was greater for glargine than
for detemir and NPH (1,538 6 688; 1,081 6 785; and 1,170 6 703 mg/kg, respectively; P ,
0.05). Glargine suppressed endogenous glucose production more than detemir (P , 0.05) and
similarly to NPH (P = 0.16). Glucagon, C-peptide, free fatty acids, and b-hydroxy-butyrate were
more suppressed with glargine than detemir. All 18 subjects completed the glargine study, but
two subjects on NPH and three on detemir interrupted the study because of plasma glucose
.150 mg/dL.
CONCLUSIONS—Compared with NPH and detemir, glargine provided greater metabolic
activity and superior glucose control for up to 32 h.
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V
eryfewstudieshaveinvestigatedthe
pharmacokinetics and pharmaco-
dynamics of NPH insulin in type 2
diabetes (1,2). These studies have pro-
vided valuable information that is limited,
however, by a short period of observation
(12–16 h) and by the comparison of NPH
with only one long-acting insulin analog,
eitherglargineordetemir.Thepresentran-
domized cross-over study was undertaken
to establish the pharmacokinetics and
pharmacodynamics of the basal insulins
NPH, glargine, and detemir in subjects
with type 2 diabetes who need insulin.
RESEARCH DESIGN AND
METHODS—After approval by the lo-
cal ethical committee, and after receiving
informed, written consent, 18 type 2 di-
abetic subjects on insulin (NPH as basal)
and/or oral hypoglycemic agents were
recruited (Supplementary Table 1) and
studied according to the Helsinki Declara-
tion and GCP requirements. This was a
randomized, single-dose, single-blind,
three-way, cross-over study that used the
previously described euglycemic glucose
clamptechnique (3).Each subject received
thethreeinsulinsby assignmenttooneof
three sequences, as directed by a Latin-
square design (ABC/BCA/CAB). After a
2-week run-in period, during which the
previoustreatmentwascontinued,subjects
were randomly assigned to a once-daily
dose of either NPH (Humulin I; Lilly and
Co., Indianapolis, IN), detemir (Levemir;
Novo Nordisk, Bagsværd, Denmark),
or glargine (Lantus; Aventis Pharma,
Frankfurt,Germany)at2200hforaperiod
of 1 week, during which titration of the
dose of basal insulin was continued. After
the7-daytreatment,allsubjectsunderwent
a euglycemic clamp for 32 h after a 0.4
units/kg subcutaneous injection at 2200 h
of the basal insulin they were on (Sup-
plementary Study Design). On the day of
the study, subjects received the last subcu-
taneous insulin (rapid-acting analog) with
the 1200-h meal and fasted afterward.
Between 1600 and 2200 h, they received
intravenous insulin to normalize plasma
glucose, as previously described (3).
Then, subjects had a 2-week wash-out pe-
riod,duringwhichtheyresumedthebasal
insulin regimen of the run-in period
(NPH). The subjects were then crossed
over to the second basal insulin according
to the randomization schedule and stud-
iedasaboveandﬁnallymovedtothethird
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last time.
Theprimaryendpointwastheglucose
infusionrate(GIR)over0–32h(areaunder
the curve [AUC]0–32 h). Secondary out-
comes are shown in the Supplementary
Data. Duration of action was deﬁned as
the minimal duration of action and end of
insulin action (calculated as the time at
which plasma glucose was .118 and 136
mg/dL, respectively). The study ended at
the time at which plasma glucose was, for
at least 30 min, .150 mg/dL (all deﬁni-
tions in the absence of glucose infusion).
Plasma glucose, C-peptide, insulin, gluca-
gon, and nonglucose substrates (free fatty
acids, b-hydroxy-butyrate, and glycerol),
aswellasglucoseﬂuxes,weremeasuredas
previously described (4) (Supplementary
Analytical Methods). During the clamp,
glucose ﬂux calculations were based on a
non–steady-state assumption (5).
Dataanalysiswascarriedoutbyusing
ANOVA for cross-over design (6) and is
Figure1—Plasmaglucose,GIR,ratesofEGPandglucoseutilization,andplasmaconcentrationsoffreefattyacids(FFAs)andb-hydroxy-butyrate
after a subcutaneous (s.c.) injection of NPH, detemir, and glargine insulin in type 2 diabetic subjects.
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RESULTS—All 18 subjects performed
the three clamp studies. However, two
and three of the 18 subjects treated with
NPH and detemir, respectively, discon-
tinued the clamp study earlier than 32 h
because of plasma glucose .150 mg/dL.
Glycemic control and insulin doses in the
week prior to the studies, as well as
plasma glucose concentration and rates
of intravenous insulin infusion prior to
the subcutaneous insulin injection at the
beginningoftheclampstudy,aregivenon-
line (Supplementary Results), likewise for
plasma insulin, plasma C-peptide, gluca-
gon, and plasma glycerol (Supplementary
Fig. 1 and Supplementary Tables 2 and 3).
T h em e a nG I Rf o rt h e3 2 - hs t u d y
period (AUC0–32 h) was greater with
glargine than NPH by 31% and detemir
by 42% (Fig. 1; Supplementary Table 2).
Endogenous glucose production (EGP)
decreased after the subcutaneous insulin
injection in all three treatments but to a
greater extent with glargine (Fig. 1). Glu-
cose utilization decreased in all treatments
and overall was no different among insulin
treatments (P = 0.268)(Fig. 1). Plasma free
fatty acid concentrations were higher
with detemir compared with NPH (+15%,
P=0.003)andglargine(+26%,P,0.001)
throughout the study, as was plasma
b-hydroxy-butyrate (Fig. 1).
Themedian timeofminimalduration
of action (plasma glucose .118 mg/dL)
and duration of action (plasma glucose
.136 mg/dL) differed among the three
treatments. Glargine exhibited a smaller
interquartile range in time of duration of
action than NPH and detemir, although
the statistical signiﬁcance was achieved
only versus detemir (Supplementary
Table 2).
Resultsofthe0-to32-hperiodandof
the 0- to 16-h and 16- to 32-h periods are
given online (Supplementary Tables 2
and 3, respectively).
CONCLUSIONS—The results of the
current study indicate that the main
outcome pharmacodynamic parameter
GIR0–32 h, taken as a surrogate measure
of insulin metabolic activity, was greater
for glargine compared with NPH and
detemir. GIR with NPH increased shortly
after the subcutaneous injection at 0400 h,
as a result of a rapid suppression of EGP
by ~50%, followed by a sensible reduc-
tion after 10–11 h because of increased
E G P ,w h i c hr e s u l t e di nas i g n i ﬁcant in-
crease in plasma glucose. This most likely
accounts for the greater risk for nocturnal
hypoglycemia reported in clinical studies
with NPH versus glargine and detemir
(7), as well as for the abnormal early-
morning increase in blood glucose known
as the “dawn phenomenon” (8). In the
second half of the study, from 1400 h,
GIR requirements for NPH and glargine
were greater than those for detemir up to
the end of the study. Likely, this was the
result of the interplay of greater activity of
NPH and glargine compared with detemir
and the afternoon increased insulin sen-
sitivity in type 2 diabetes (9). This ﬁnding
is in line with the observation of more fre-
quent predinner hyperglycemia and/or
need for twice-daily detemir dosing in
clinical studies compared with glargine
(10). Finally, glargine had greater effects
on suppression of lipolysis than NPH and
detemir. Compared with detemir only,
glargine suppressed more C-peptide and
glucagon concentrations. In addition, it
had a longer duration of action with lower
variability across subjects, as suggested by
the smaller interquartile range.
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